Both in vitro and in vivo experiments demonstrate that treating myeloma cells with PD‐L1 antibodies post‐chemotherapy significantly enhances the killing efficiency of activated T cells, compared to sequential treatment with chemotherapy and PD‐L1 antibodies. This evidence concerns the gene CD274 and plasma cell myeloma.